-+ 0.00%
-+ 0.00%
-+ 0.00%

IP Group’s Enterprise Therapeutics Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis

路透·12/09/2025 15:34:58

登錄查看新聞詳情